Safety and Immunogenicity of the Malaria Vaccine Candidate MSP3 Long Synthetic Peptide in 12–24 Months-Old Burkinabe Children

BACKGROUND: A Phase Ia trial in European volunteers of the candidate vaccine merozoite surface protein 3 (MSP3), a Plasmodium falciparum blood stage membrane, showed that it induces biologically active antibodies able to achieve parasite killing in vitro, while a phase Ib trial in semi-immune adult...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Sirima, Sodiomon B., Tiono, Alfred B., Ouédraogo, Alphonse, Diarra, Amidou, Ouédraogo, André Lin, Yaro, Jean Baptiste, Ouédraogo, Espérance, Gansané, Adama, Bougouma, Edith C., Konaté, Amadou T., Kaboré, Youssouf, Traoré, Abdoulaye, Roma, Chilengi, Soulama, Issiaka, Luty, Adrian J. F., Cousens, Simon, Nébié, Issa
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2009
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2764341/
https://ncbi.nlm.nih.gov/pubmed/19855847
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0007549
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados